Lonza Group AG Share Price

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 11:48:56 15/05/2024 BST 5-day change 1st Jan Change
524.3 CHF +3.33% Intraday chart for Lonza Group AG -0.65% +47.87%

Financials

Sales 2024 * 6.66B 7.35B 583B Sales 2025 * 7.61B 8.4B 666B Capitalization 36.59B 40.41B 3,204B
Net income 2024 * 891M 984M 78.02B Net income 2025 * 1.1B 1.21B 96.15B EV / Sales 2024 * 5.95 x
Net Debt 2024 * 3B 3.31B 262B Net Debt 2025 * 3.39B 3.75B 297B EV / Sales 2025 * 5.26 x
P/E ratio 2024 *
41.1 x
P/E ratio 2025 *
33 x
Employees 18,000
Yield 2024 *
0.89%
Yield 2025 *
1.03%
Free-Float 95.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.23%
1 week-0.65%
Current month+2.47%
1 month-2.06%
3 months+14.09%
6 months+48.88%
Current year+47.87%
More quotes
1 week
499.40
Extreme 499.4
533.40
1 month
497.60
Extreme 497.6
533.40
Current year
339.00
Extreme 339
559.40
1 year
308.60
Extreme 308.6
599.40
3 years
308.60
Extreme 308.6
785.40
5 years
301.00
Extreme 301
785.40
10 years
89.30
Extreme 89.3
785.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 24/04/17
Director of Finance/CFO 52 30/11/21
Chief Operating Officer 55 31/07/22
Members of the board TitleAgeSince
Director/Board Member 63 15/04/14
Director/Board Member 66 15/04/14
Director/Board Member 58 04/05/22
More insiders
Date Price Change Volume
15/05/24 522.8 +3.04% 64 224
14/05/24 507.4 -1.74% 400,971
13/05/24 516.4 -1.86% 181,129
10/05/24 526.2 -0.04% 172,626
08/05/24 526.4 +1.19% 164,659

Delayed Quote Swiss Exchange, May 15, 2024 at 11:33 am

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
507.4 CHF
Average target price
576.9 CHF
Spread / Average Target
+13.69%
Consensus